| Citation | Professor Daniel Drucker, Professor of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
Daniel Drucker is nominated for pioneering studies of gut hormone action enabling development of three new classes of medications for treatment of diabetes and short bowel syndrome (SBS). He demonstrated that GLP-1 stimulates insulin secretion in 1987, cloned cDNAs for GLP-1 and exendin-4, and generated Glp1r-/- mice, identifying multiple new cardiometabolic actions of GLP-1. Drucker demonstrated that Dpp4 was essential for glucose homeostasis and identified GIP and GLP-1 as the key substrates transducing glucoregulatory actions of DPP-4 inhibitors. He discovered the first actions of GLP-2, characterized GLP-2 metabolism, and developed teduglutide, the first GLP-2 analogue approved for treatment of SBS.
|